Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

Exclusion Criteria

• •1. Any contraindication or known allergies to Lephanet®, Thealoz Duo®, MGD Rx EyeBag® or Softacort®
• •2. Ocular surgery in the past 6 months
• •3. Ocular hypertension or glaucoma
• •4. Cicatricial MGD
• •5. Atopic condition including ocular allergy
• •6. Suspect demodex lid infestation as evidenced by the presence of collarettes
• •7. Intraocular inflammation
• •8. Confirmed infection with COVID-19 in the last 3 months
• •9. Systemic autoimmune disorder
• •10. Use of contact lenses during the month prior to inclusion in the study or during the study
• •11. Punctal occlusion
• •12. Intraocular pressure \> 22 mmHg
• •13. Patient who has received topical or systemic anti-inflammatory treatments including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDS) within 3 months prior to be included in the study or with a prescription for receiving topical / systemic anti-inflammatory treatments for the next 3 months
• •14. In the investigator´s opinion, use of systemic medications that could affect the function of the meibomian gland and tear production within 3 months prior to be included in the study
• •15. Any ocular or systemic disease known to affect the tear film other than MGD
• •16. Patient with any situation or state that in the opinion of the investigator discourages their participation in the study
• •17. Patient participating in any other interventional or non-interventional study or who have participated in another study within 30 days prior to inclusion in this study
• •18. Women who are pregnant, planning to become pregnant or breastfeeding
• •19. Patient who will not be able to complete the study (e.g., not willing to attend the follow-up visits, way of life interfering with compliance)